KML29

SKU: orb1303231

Description

KML29 is a potent and selective monoacylglycerol lipase (MAGL) inhibitor, effective across human, mouse, and rat enzymes while showing no activity against FAAH. It selectively elevates brain 2-AG levels in vivo, making it a valuable research tool for studying endocannabinoid signaling in neurological and inflammatory disease models.

Research Area

Metabolism Research

Key Properties

• CAS Number: 1380424-42-9
• MW: 549.42
• Purity: 98.65% (May vary between batches)
• Formula: C₂₄H₂₁F₆NO₇
• SMILES: OC(C1CCN(CC1)C(=O)OC(C(F)(F)F)C(F)(F)F)(c1ccc2OCOc2c1)c1ccc2OCOc2c1
• Target: MAGL,Lipase
• Solubility: DMSO:50 mg/mL (91.01 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (3.64 mM)

Bioactivity

• Target IC50:
  MAGL (mouse):15 nM|AEA:>50 μM|2-AG:2.5 nM|MAGL (human):5.9 nM|MAGL (rat):43 nM
• In Vivo:
  DprE1-IN-2 has efficacy in a rodent model of tuberculosis.

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

LPS, Monoacylglycerol lipase, KML 29, KML29, KML-29, inhibit, Inhibitor, HFIP, MAGL, allodynia, 2-AG

Compound Identifiers

PubChem CID

71656212